Jury convicts SAC fund manager for insider trading

Eric Palmer The highly publicized insider trading case against SAC Capital Advisors trader Mathew Martoma has finally come to a conclusion–at least for now. FiercePharma News

U.S. rep rips the FDA’s efforts to speed up drug approvals

Damian Garde Over the past few years, the FDA has unveiled a spate of new approval pathways in hopes of getting much-needed treatments on the market faster. But in the rush to accelerate ...

Innate goes it alone on a cancer drug, buying out Novo for up to $30M

Damian Garde France's Innate Pharma has signed a deal to pay Novo Nordisk $ 2.7 million up front and as much as $ 27 million in milestones for exclusive rights to the pair's ...

CFR and Adcock Ingram give up on their transcontinental merger

Eric Palmer The planned transcontinental marriage between South America's CFR and South Africa's Adcock Ingram had been on shaky grounds for some time. But the engagement has ...

AbbVie picks Singapore for a $320M production facility

John Carroll Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis, GlaxoSmithKline and Amgen. Even Russia's Pharmstandard has an API facility there. ...

Singapore fling: AbbVie says a plant in Asia is just what it needs

Eric Palmer Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products ...

Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success

John Carroll FierceBiotech News

Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Tracy Staton Indian drugmakers have a shot at bringing Gilead Sciences' hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" ...

Novartis slashing thousands more jobs in global reorganization, shifting many to India

Tracy Staton Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, ...

Wellcome ponies up $20M to kick-start an Oxford spinoff

Damian Garde With the help of Syncona, the Wellcome Trust's venture arm, Oxford University spinout NightstaRx has $ 20 million and a plan to develop gene therapies for degenarative ...

Merck lays off its simian staff as the industry moves away from chimp research

Damian Garde Merck has joined the growing list of entities pulling the plug on chimpanzee research, folding to activist pressure and dismissing its primate subjects once and for all. FierceBiotech ...

FDA investigating heart and stroke risks of using testosterone to treat ‘low T’

Eric Palmer The FDA has been monitoring the stroke and heart risks of testosterone-enhancing drugs, which have become popular among baby-boomer men trying to hold onto their middle-aged ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS